What is the Future of Unconjugated Antibodies in Cancer Treatment?
Research is ongoing to improve the efficacy and safety of unconjugated antibodies. Innovations include:
Bispecific Antibodies: These are engineered to target two different antigens simultaneously, potentially offering greater efficacy. Combination Therapies: Combining unconjugated antibodies with other treatments like checkpoint inhibitors, CAR-T cell therapy, and small molecule inhibitors to overcome resistance and improve outcomes. Personalized Medicine: Advances in genomics and biomarker discovery are enabling more personalized approaches, tailoring antibody treatments to the unique characteristics of an individual’s cancer.
